Phase I open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-6827 administered IV weekly X 3, repeated every 28 days, in subjects with refractory solid tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2009
At a glance
- Drugs Verubulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Myrexis
- 23 Nov 2009 New source identified and integrated M.D. Anderson Cancer Center, 2005-0091).
- 30 Nov 2005 New trial record.